Prognostic impact of <i>DNMT3A</i> mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia

Abstract

We have confirmed the high incidence of DNMT3A mutations in patients with AML with IR cytogenetics. Patients with DNMT3A mutations relapse more often and have inferior OS when only patients achieving CR are analyzed. 'Double-mutated' patients have a very poor prognosis.